Asia Deal Watch: Athenex Changes Mind, Gets Back Chinese Rights To Actinic Keratosis Candidate

2019-03-15
BioPortfolio
并购
Following a positive Phase III data readout for KX2-391, Athenex requests dissolution of its recent deal conferring rights to the... Related Stories Shorter Treatment Time For Chagas Could Blunt Kissing Bug Disease Sandoz Head Francis To Leave Amid Move Towards Autonomy Vifor Pharma: Targets Acquisitions As Pure-Play Strategy Delivers
机构
-
适应症
靶点
-
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。